MenoFix™ - References
|I Product Info||I Ingredients
||I Recommended Use
||I Clinical Trials
||I Research Brief
Low USA domestic & international shipping
Indication: premenstrual syndrome, hormonal imbalance, estrogen deficiency, menstrual irregularities.
Actions: helps normalize female hormonal balance, reduces the premenstrual syndrome (PMS) symptoms, supports the health of female reproductive system, strengthens the nervous system, vitamin and mineral support for women’s health.
Ingredients (per 1 capsule):
vitamin A (as beta carotene) – 2000 IU, vitamin C (as ascorbic acid, calcium ascorbate, ascorbyl palmitate, acerola (Malpighia glabra L) 4:1 fruit extract, rose hips (Rosa rugosa) powder) – 30 mg, vitamin E (as d-alfa-tocopheryl succinate) – 15 IU, thiamin (as thiamin HCl) – 2 mg, riboflavin – 0.9 mg, niacin (as niacin and niacinamide) – 15 mg, vitamin B6 (as pyridoxine HCl) – 3 mg, folate – 200 mcg, vitamin B12 (as cyanocobalamin) – 2.5 mcg, iron (as carbonyl iron) – 7 mg, iodine (from Ascophyllum nodosum) – 50 mcg, zinc (as zinc citrate) – 7.5 mg, selenium (as selenium + GPM) – 35 mcg, copper (as copper gluconate)– 1 mg, black cohosh (Cimicifuga racemosa)) (12:1) root extract [8% triterpene glycosides (as 27-deoxyactein)] (equivalent to 78 mg of crude herb) – 6.5 mg, chaste tree (Vitex agnus-castus) berry extract (4:1) (0.5% total agnusides and 0.15% aucubin) (equivalent to 1000 mg of crude herb) – 250 mg.
MenoFix™ - References:
1. Miller KK, Parulekar MS, Schoenfeld E, et al. Decreased leptin levels in normal weight women with hypothalamic amenorrhea: the effects of body composition and nutritional intake. J Clin Endocrinol Metab 1998;83:2309-12.
2. Snow RC, Schneider JL, Barbieri RL. High dietary fiber and low saturated fat intake among oligomenorrheic undergraduates. Fertil Steril 1990;54:632-7.
3. Warren MP, Holderness CC, Lesobre V, et al. Hypothalamic amenorrhea and hidden nutritional insults. J Soc Gynecol Investig 1994;1:84-8.
4. Berga SL, Loucks-Daniels TL, Adler LJ, et al. Cerebrospinal fluid levels of corticotropin-releasing hormone in women with functional hypothalamic amenorrhea. Am J Obstet Gynecol 2000;182:776-81.
5. Gallinelli A, Matteo ML, Volpe A, Facchinetti F. Autonomic and neuroendocrine responses to stress in patients with functional hypothalamic secondary amenorrhea. Fertil Steril 2000;73:812-6.
6. Johnson J, Whitaker AH. Adolescent smoking, weight changes, and binge-purge behavior: associations with secondary amenorrhea. Am J Public Health 1992;82:47-54.
7. Bone K. Vitex agnus-castus: Scientific studies and clinical applications. Eur J Herbal Med 1994;1:12–5.
8. Milewicz A, Gejdel E, Sworen H, et al. Vitex agnus castus extract for the treatment of menstrual irregularities due to latent hyperprolactinemia. Arzneim Forsch 1993;43:752–6
9. Amann W. Improvement of acne vulgaris following therapy with Agnus castus (Agnolyt). Ther Ggw 1967;106:124–6 [in German].
10. Loch EG, Katzorke T. Diagnosis and treatment of dyshormonal menstrual periods in general practice. Gynäkol Praxis 1990;14:489-95.
11. Sliutz G, Speiser P, Schultz AM, et al. Agnus castus extracts inhibit prolactin secretion of rat pituitary cells. Horm Metab Res 1993;25:253-5.
12. Schellenberg R. Treatment for the premenstrual syndrome with agnus castus fruit extract: prospective, randomized, placebo controlled study. BMJ 2001;20:134
13. Brown D, Herbal Research Review: Vitex agnus castus Clinical Monograph. Quarterly Review of Natural Medicine Summer 1994.
14. Mediherb Newsletter, October 1994, Mediherb Phy Ltd, Queensland, Australia.